The US FDA has removed a clinical hold for Kolon TissueGene Inc.’s allogeneic cell and gene therapy for knee osteoarthritis Invossa (TissueGene-C; tonogenchoncel-L), which was undergoing Phase III trials.
The long-awaited decision has provided a glimpse of light for Kolon TissueGene, formerly known as TissueGene Inc., and parent...







